https://www.youtube.com/watch?v=MWD0jXtvHNs
In this Power Bite, @LeoandLongevity Mark Bell, Nsima Inyang, and Andrew Zaragoza talk about the effects of Ibogaine on Opiate withdrawal and brain function

https://www.sciencedirect.com/science/article/pii/S295019972300006X
Tabernanthe iboga, also known as Iboga, is renowned for its antiaddictive properties and its psychedelic effects in individuals following the consumption of high doses.Yet, consumption of iboga has also been associated with some cases of fatalities. The objective of this review is to explore the mechanisms involved in the neuroprotection and the neurotoxicity of iboga, particularly ibogaine

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6157925/
Ibogaine history and evidence for use as a treatment for opioid addiction. Ibogaine is a naturally occurring alkaloid, obtained from the root bark of the African shrub Tabernanthe iboga, and is also produced through semi-synthesis of voacangine from the African tropical tree Voacanga africana.Iboga was historically used as a medicinal and ceremonial agent in indigenous cultures in West Central

https://www.sciencedirect.com/science/article/pii/S0079612318300979
Ibogaine may work in reversing the effects of opiates on gene expression, with resulting impacts on neuroreceptors, returning them to a pre-addiction condition (Brackenridge, 2010). Furthermore, addictive loops and pathways in the brain are reversed (He et al., 2005). 1.4. Pharmacology, Pharmacokinetics and Pharmacodynamics

https://time.com/5951772/ibogaine-drug-treatment-addiction/
"Ibogaine seems to resolve these signs of opioid withdrawal by a mechanism that is different from an opioid effect, and I think that is what is so interesting about it," says Dr. Kenneth Alper

https://pubmed.ncbi.nlm.nih.gov/28541119/
Background: Ibogaine is a monoterpene indole alkaloid used in medical and nonmedical settings for the treatment of opioid use disorder. Its mechanism of action is apparently novel. There are no published prospective studies of drug use outcomes with ibogaine. Objectives: To study outcomes following opioid detoxification with ibogaine.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9190277/
Ibogaine and its principal active metabolite, noribogaine, bind to the transporters for the monoamines SER, DA, and NE. For example, ibogaine ingestion has been linked to several deaths by cardiac arrest. Nonetheless, recent studies suggests that its actions at nicotinic acetylcholine receptor subtypes may underlie its reputed anti-opiate effects.

https://dashboard.commons.pacificu.edu/downloads/c901e306-5ae8-4065-b342-6a29b27aa5fc
observational cohort studies. All studies showed that Ibogaine can mitigate withdrawal and cravings in patients with opioid use disorder. Conclusion: Ibogaine has been associated with decreased withdrawal and cravings in patients with Opioid Use Disorder, and may be considered as an adjunct to existing treatment modalities. Keywords:

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11102648/
The clearance of ibogaine is strongly related to CYPD2D6 genotype. Ibogaine cardiac side effects (QTc time) and cerebellar effects are most likely more driven by ibogaine rather than noribogaine. Future studies should aim at exploring lower doses and/or applying individualized dosing based on CYP2D6 genotype.

https://www.tandfonline.com/doi/pdf/10.1080/17425255.2021.1944099
including opioid withdrawal, and opioid, alcohol, cocaine and nicotine self-administration. In a recent meta-analysis of 27 published animal studies, drug self-administration was most significantly reduced in the first 24 hours after treatment with ibogaine, and these effects were sustained for more than

https://pubmed.ncbi.nlm.nih.gov/28402682/
Background: The psychoactive indole alkaloid ibogaine has been associated with encouraging treatment outcomes for opioid dependence. The legal status of ibogaine in New Zealand provides a unique opportunity to evaluate durability of treatment outcomes. Objective: To examine longitudinal treatment effects over a 12-month period among individuals receiving legal ibogaine treatment for opioid

https://open.bu.edu/bitstream/handle/2144/27421/Nielsen_bu_0017N_13442.pdf?sequence=5
Ibogaine is a naturally occurring indole alkaloid that may be an effective alternative form of treatment for individuals struggling with opiate addiction and/or withdrawal. Preliminary research has found that iboga alkaloids such as ibogaine are effective at reducing morphine self-administration in rats. An elaborate history of human case reports

https://www.nytimes.com/2024/03/05/health/ibogaine-psychedelic-opioid-addiction.html
March 5, 2024. Ibogaine, a formidable psychedelic made from the root of a shrub native to Central Africa, is not for the timid. It unleashes a harrowing trip that can last more than 24 hours, and

https://pubmed.ncbi.nlm.nih.gov/1504783/
Ibogaine, an indolalkylamine, proposed for use in treating opiate and stimulant addiction, has been shown to modulate the dopaminergic system acutely and one day later. In the present study we sought to systematically determine the effects of ibogaine on the levels of dopamine (DA) and the dopamine

https://www.tandfonline.com/doi/full/10.1080/00952990.2017.1310218
ABSTRACT. Background: The psychoactive indole alkaloid ibogaine has been associated with encouraging treatment outcomes for opioid dependence.The legal status of ibogaine in New Zealand provides a unique opportunity to evaluate durability of treatment outcomes. Objective: To examine longitudinal treatment effects over a 12-month period among individuals receiving legal ibogaine treatment for

https://onlinelibrary.wiley.com/doi/10.1080/105504999305848
Ibogaine is an alkaloid with putative effect in acute opioid withdrawal. Thirty-three cases of treatments for the indication of opioid detoxification performed in non-medical settings under open label conditions are summarized involving an average daily use of heroin of .64 ± .50 grams, primarily by the intravenous route.

https://psychable.com/iboga-ibogaine/how-does-ibogaine-work
It can block or greatly diminish acute withdrawal effects of opioids, making it particularly well suited for treating opioid use disorders (OUD) involving classic opiates like morphine and heroin. In this article, we'll explore the science behind how ibogaine impacts the body and brain and provide a discussion on the dosing of ibogaine in OUD.

https://www.iceers.org/Documents_ICEERS_site/Scientific_Papers/ibogaine/Alper%20et%20al_1999_Acute_Opiate_Withdrawal.pdf
Detoxi. cation is a necessary step in the treatment of opioid dependence. Ibo-gaine, an indole alkaloid found in the bark of the root of the African shrub Tabernan-the iboga, is alleged to have anti-addictive qualities, including ef cacy in acute opioid withdrawal.1 The Medications Development Division of the National Institute on Drug Abuse

https://psychable.com/addiction/the-new-era-of-ibogaine-treatment-and-opiates-what-you-need-to-know-for-a-successful-experience
Ibogaine is well known for its role in opiate addiction treatment. Ibogaine has been shown to eliminate acute opiate withdrawal symptoms and diminish or eliminate post-acute withdrawal syndrome (PAWS) often in a single treatment. Ibogaine is also known for its visionary state. Ibogaine's dream-like state is not fully understood but is most

https://psychedelic.support/resources/ibogaine-substance-guide/
The typical dose of ibogaine for a psychedelic effect is 15-20 mg per kg. Research has found several receptors that ibogaine binds to and acts upon: Like other psychedelic drugs, ibogaine inhibits serotonin reuptake in the brain. This leads to greater amounts of serotonin for binding to the serotonin receptors.

https://www.healthline.com/health/ibogaine-treatment
Treatment. Ibogaine acts as a mild stimulant in small doses. In large doses, it can put a person into a severe psychedelic state. Some people have found that large doses reduce opiate withdrawal

https://bbrfoundation.org/content/small-preliminary-trial-psychoactive-drug-ibogaine-yields-initial-evidence-powerful
In an exploratory and preliminary clinical test, a team of researchers at Stanford University has obtained "initial evidence" suggesting that a psychoactive compound called ibogaine, when co-administered with magnesium, "could be a powerful therapeutic" to safely treat a variety of psychiatric symptoms, including PTSD, major depression and anxiety, and suicidality, all of which may e

https://www.medicalnewstoday.com/articles/ibogaine-for-addicition
Some research suggests that ibogaine, a Schedule I controlled substance, may help reduce symptoms of drug and alcohol withdrawal, ease cravings, and reduce the risk of relapse. Learn more.

https://www.acsh.org/news/2024/06/21/if-opiates-are-killing-americans-why-wont-fda-let-us-try-alternative-48824
As the DEA relentlessly tightens regulations on pain meds, the FDA refuses to approve a safer alternative already being used in similar countries. With Dr. Jeffrey Singer. For more than a decade, patients who've needed certain controlled medications have suffered from ill-advised, untenable policies

https://www.centralmaine.com/2024/06/21/augusta-to-use-opiate-settlement-funds-to-pay-for-mental-health-worker-on-police-calls/
Councilors also approved the use of $10,000 of Augusta's opioid settlement funds, which currently totals around $530,000 in the bank, to be set aside to help people ready to enter substance use

https://www.cbs8.com/article/news/local/ucsd-researchers-artificial-intelligence-opioid-addiction/509-e97d7f2b-8be9-4762-960b-67bdd181fc2b
"A patient's healthcare journey changes everyday, if we can track using the electronic medical records system how their risk changes as their healthcare changes and let doctors know hey because of

https://www.bbc.com/news/articles/c0vv3q92zq9o
Woman's hopes for brain tumours breakthrough. 14 mins ago. Former drug users to help prevent opiate overdoses. 14 hrs ago. England. Two vehicle fires believed to be arson - police.

https://www.bostonherald.com/2024/06/24/letters-to-the-editor-633/
While we must remain focused on the crushing effects related to opioid addiction, we must also re-focus on the overwhelming number of people in the Commonwealth that need support for alcohol

https://www.justice.gov/usao-edca/pr/madera-pharmacist-pleads-guilty-trafficking-hundreds-thousands-opiate-pills
FRESNO, Calif. — Fresno residents Ifeanyi Vincent Ntukogu, 49, and Kelo White, 43, pleaded guilty today to conspiring to distribute and distributing oxycodone and hydrocodone, U.S. Attorney Phillip A. Talbert announced.

https://casetext.com/statute/colorado-revised-statutes/title-22-education/general-and-administrative/article-1-general-provisions/section-22-1-1191-effective-872024-policy-for-employee-and-agent-possession-and-administration-of-opiate-antagonists-definitions
Section 22-1-119.1 - [Effective 8/7/2024] Policy for employee and agent possession and administration of opiate antagonists - definitions (1) A school district board of education of a public school, the state charter school institute for an institute charter school, or the governing board of a nonpublic school may adopt and implement a policy whereby: (a) A school under its jurisdiction may